Arthritis, Joint Pains
|
New Onset Psoriatic Arthritis Reported in Psoriasis Patients Treated with Efalizumab
|
The T-cell inhibitor efalizumab (Raptiva) has demonstrated efficacy in the treatment of moderate to severe plaque psoriasis. However, it has not demonstrated efficacy for the treatment of psoriatic arthritis and, in one study, was associated with worsening of arthritis symptoms. Only a minority of individuals with psoriasis have a concomitant inflammatory arthritis, making therapy with efalizumab an option for the treatment of a large number of psoriasis patients who have no articular involvement.
|
|
Denosumab, an inhibitor of RANKL, suppresses erosions but has no effect on articular signs and symptoms in rheumatoid arthritis
|
Bone erosions in response to inflammation in RA are driven by osteoclasts which are in turn activated by RANKL (Receptor Activator for Nuclear Factor κ B Ligand) binding to its receptor RANK. Inhibition of RANKL has the potential to retard bone erosions in RA patients, thereby limiting progressive joint damage and destruction..........
|
|
Denosumab, an inhibitor of RANKL, suppresses erosions but has no effect on articular signs and symptoms in rheumatoid arthritis
|
Bone erosions in response to inflammation in RA are driven by osteoclasts which are in turn activated by RANKL (Receptor Activator for Nuclear Factor κ B Ligand) binding to its receptor RANK. Inhibition of RANKL has the potential to retard bone erosions in RA patients, thereby limiting progressive joint damage and destruction..........
|
|
Barriers to Urate Lowering Therapy Explored
|
Urate lowering therapy can be very effective for reducing flares of gout, thereby preventing ongoing joint damage and deformity. Despite this efficacy, most gout patients are undertreated, leading to undue painful flares and joint damage. Non-adherence to therapy is a strong contributor to undertreatment..........
|
|
Golimumab Shows Promise for the Treatment of Rheumatoid Arthritis
|
There are currently three TNF agents on the market for RA; among these, infliximab is a chimeric monoclonal antibody against TNF-α administered as an infusion. Golimumab is similar to infliximab, except that it has been engineered to be fully human and is given as a subcutaneous injection...........
|